GSK licenses breast cancer drug rights to Chinese firm

04/10/2013 | Pharmaceutical Business Review Online

GlaxoSmithKline China granted Eddingpharm exclusive rights to import, promote, market and distribute breast cancer drug Tykerb, or lapatinib, in mainland China. With capecitabine, Tykerb is used for patients with HER2-positive metastatic breast cancer who previously received anthracycline, a taxane and trastuzumab.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN